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ASBESTOS FRAUD SHOULD LEAD TO FAIRNESS: WHY
CONGRESS SHOULD ENACT THE FAIRNESS IN
ASBESTOS INJURY RESOLUTION ACT
ELISE GELINAS*
In response to the unique characteristics of asbestos litigation,
courts developed “special asbestos law” to facilitate the management
of asbestos dockets.1 Special asbestos law, however, tipped the scale of
justice in favor of plaintiffs by compelling defendant companies to settle mass quantities of claims at one time.2 As plaintiffs’ firms responded opportunistically to their success by developing screening
measures to recruit hundreds of thousands of claimants, asbestos litigation reached crisis status.3 On numerous occasions, the Supreme
Court of the United States, recognizing that the judiciary was incapable of managing asbestos dockets, called for an administrative
solution.4
As Congress began to consider an administrative solution, however, the plaintiffs’ asbestos bar shifted focus due to fear that their
investment in unimpaired asbestos claimants would become lost upon
the enactment of legislation.5 Because silica shares numerous characteristics with asbestos, plaintiffs’ firms directed their screening companies to recruit silicosis claimants.6 But when the Judicial Panel on
Copyright  2009 by Elise Gelinas.
* Elise Gelinas is a third-year student at the University of Maryland School of Law
where she is the Executive Articles Editor for the Maryland Law Review. The author would
like to thank Professor Donald Gifford for his guidance and invaluable knowledge of mass
tort litigation. The author would also like to thank Professor Danielle Citron for her unyielding support and Lindsay Goldberg, Executive Notes and Comments Editor, for her
excellent editing. Lastly, the author is especially grateful for the continued support and
encouragement from her family.
1. See infra Part I.
2. See infra Part I.A.
3. See infra Part I.
4. See, e.g., Ortiz v. Fibreboard Corp., 527 U.S. 815, 821 (1999) (“[Asbestos] litigation
defies customary judicial administration and calls for national legislation.”); Amchem
Prods., Inc. v. Windsor, 521 U.S. 591, 628–29 (1997) (“[A] nationwide administrative
claims processing regime would provide the most secure, fair, and efficient means of compensating victims of asbestos exposure.”).
5. See infra Part III.
6. See infra Part III.
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Multidistrict Litigation aggregated thousands of silicosis claims in the
United States District Court for the Southern District of Texas, a historical opinion followed.7 United States District Court Judge Janis
Graham Jack found that almost all of the 10,000 silicosis diagnoses in
her courtroom had been fraudulently manufactured.8 Although her
opinion dealt with silica litigation, Judge Jack’s findings significantly
affect asbestos reform. By conducting Daubert hearings and court depositions that exposed the prevalence of fraud in silica litigation, Judge
Jack exposed the prevalence of fraud in asbestos litigation as well.9 As
a result, it is reasonable to conclude that the number of asbestos
claims compensated through the tort system was greatly inflated due
to fraud.10
Despite this watershed event, the Fairness in Asbestos Injury Resolution Act (“FAIR Act”)—Congress’s attempt to enact an administrative solution to asbestos litigation—failed in the Senate in 2006.11
One of the main reasons why the FAIR Act collapsed was because its
drafters were concerned about their ability to predict the number of
claims that would be filed with the administrative fund.12 Using the
tort system and asbestos trust funds as a guide, the Congressional
Budget Office concluded that the fund would need approximately
$140 billion to pay all future legitimate asbestos claims.13 Many feared
that this estimate was too low; thus, the FAIR Act failed because it was
unable to provide defendant companies and their insurers with certainty about their asbestos-related expenditures.14
The Congressional Budget Office, as well as the senators who supported the FAIR Act, erred by failing to fully appreciate Judge Jack’s
findings regarding the prevalence of fraud in asbestos litigation.15 By
failing to accord her opinion its deserved significance, the Senate did
not realize that the tort model they were relying on to predict claims
had a grossly inflated number of asbestos claims due to fraud.16 As a
result, the concern that $140 billion would be insufficient to compensate all future claimants was unfounded.17 Because of Judge Jack’s
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
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findings and their implications, the FAIR Act should not have collapsed out of fear that the administrative system would receive too
many claims.18 In fact, Judge Jack’s opinion should have reassured
Congress that such a solution was more necessary than ever.19
I.

THE EVOLUTION OF ASBESTOS LITIGATION: FROM “THE WORST
OCCUPATIONAL HEALTH DISASTER IN U. S. HISTORY”20 TO AN
“ASBESTOS-LITIGATION CRISIS”21

Asbestos litigation possesses unique characteristics that have enabled it to become the longest-running mass tort litigation in the
United States.22 Tens of millions of Americans have been exposed to
asbestos,23 resulting in asbestos-related injuries such as mesothelioma,
asbestosis, pleural plaques and thickening, and other cancers.24 As of
2002, approximately 730,000 people have filed asbestos-related
claims,25 which has cost defendants and their insurers around $70 billion.26 The distinguishing feature of asbestos litigation, however, is its
ability to evolve over time.27
Numerous factors have enabled asbestos litigation to reshape itself over time. First, the complex nature of asbestos-related injuries
enables the litigation to adapt and overcome barriers that would have
ended other mass tort litigation.28 Asbestos litigation is complex be18. See infra Part V.
19. See infra Part V.
20. Stephen J. Carroll et al., Asbestos Litigation Costs and Compensation: An Interim Report,
2002 RAND INST. FOR CIV. JUST. 16 [hereinafter RAND 2002] (citation and internal
quotation marks omitted).
21. Amchem Prods., Inc. v. Windsor, 521 U.S. 591, 597 (1997).
22. Stephen J. Carroll et al., Asbestos Litigation, 2005 RAND INST. FOR CIV. JUST. 21–22
[hereinafter RAND 2005].
23. Id. at 2.
24. Id. at 12. Mesothelioma is a cancer of the lining in the chest or abdomen and is
considered inevitably fatal. Id. Asbestosis, a chronic lung disease, causes decreased lung
capacity and can be debilitating or fatal. Id. at 13. Pleural plaques and pleural thickening
are scarring of the membrane lining the chest wall and lungs, a nonmalignant abnormality.
Id. at 14. The relationship between asbestos exposure and other cancers is controversial,
but some claim the following are asbestos-related injuries: “leukemia[ ] and cancers of the
bladder, breast, colon, esophagus, kidney, larynx, lip, liver, lymphoid, mouth, pancreas,
prostate, rectum, stomach, throat, thyroid, and tongue.” Id. at 13.
25. Id. at 71.
26. Id. at 92. After transaction costs, however, claimants’ net compensation is only
about 42% of this sum. Id. at 104. Additionally, asbestos litigation has bankrupted approximately eighty companies. John Wylie et al., Trial Lawyers Inc. Asbestos: A Report on the Asbestos Litigation Industry, 2008 MANHATTAN INST. CENTER FOR LEGAL POL’Y 2.
27. RAND 2005, supra note 22, at 21.
28. Patrick M. Hanlon & Anne Smetak, Asbestos Changes, 62 N.Y.U. ANN. SURV. AM. L.
525, 604–05 (2007).
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cause millions of people used asbestos in a wide variety of settings over
several decades, exposure resulted in both minor and serious injuries
with long latency periods, and numerous companies could be held
responsible for the same exposures.29 Second, with billions of dollars
of profit at stake, a creative asbestos bar has fought to keep asbestos
litigation long-lasting.30 For example, plaintiffs’ firms have developed
entrepreneurial methods to recruit vast numbers of claimants, have
sought clients with both cancerous and nonmalignant injuries, and
have exploited favorable jurisdictions.31 Further, when the JohnsManville trust fund (“Manville Trust”)32 became insolvent, the asbestos bar adapted by targeting companies with a more remote connection to asbestos and by developing new types of claims.33
A. The Fifth Circuit’s Decision in Borel v. Fibreboard Paper
Products Corp. Catalyzed Mass Asbestos Litigation
Until Borel v. Fibreboard Paper Products Corp.,34 employees of asbestos-products manufacturers had to rely on workers’ compensation
claims to recover for asbestos-related injuries.35 In Borel, however, the
United States Court of Appeals for the Fifth Circuit determined that
these manufacturers had failed to warn their employees about asbestos—an unreasonably dangerous product—and thus should be held
strictly liable for resulting injuries.36 After the Borel decision, product
liability claims against asbestos manufacturers rapidly increased, and
by the early 1980s, the number of claims reached more than 20,000.37
During the 1990s, the number of claims exceeded 200,000.38
In some jurisdictions, federal and state courts struggled with how
to best manage their asbestos caseloads.39 Overwhelmed by the number of cases on their dockets, some judges adopted a formal approach
29. Id.
30. Id. at 605.
31. Id.
32. When the Johns-Manville Corporation filed for bankruptcy, the bankruptcy court
established the Manville Trust so that all present and future claimants could be compensated for their asbestos-related injuries. Ronald Barliant et al., From Free-Fall to Free-For-All:
The Rise of Pre-Packaged Asbestos Bankruptcies, 12 AM. BANKR. INST. L. REV. 441, 447–48
(2004).
33. Hanlon & Smetak, supra note 28, at 605.
34. 493 F.2d 1076 (5th Cir. 1973), cert. denied, 419 U.S. 869 (1974).
35. Christopher J. O’Malley, Breaking Asbestos Litigation’s Chokehold on the American Judiciary, 2008 U. ILL. L. REV. 1101, 1106–07.
36. Borel, 493 F.2d at 1106.
37. RAND 2005, supra note 22, at 1.
38. David C. Landin et al., Lessons Learned from the Front Lines: A Trial Court Checklist for
Promoting Order and Sound Policy in Asbestos Litigation, 16 J.L. & POL’Y 589, 595 (2008).
39. RAND 2005, supra note 22, at 28.
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to managing asbestos litigation, while other judges adopted more informal approaches.40 Regardless of these judges’ intentions, many of
their substantive and procedural shortcuts were ill-fated.41 For example, one of the key features of such judicial management included the
aggregation or consolidation of cases for pretrial processing.42 By allowing plaintiffs to aggregate and consolidate their claims—consisting
of different alleged injuries, causes of action, and time periods—
courts gave plaintiffs an advantage.43
Using courts’ “special asbestos law,”44 plaintiffs’ counsel developed strategies to coerce defendant companies to settle claims en
masse.45 For example, plaintiffs’ counsel would group hundreds or
thousands of claims together, where claimants ranged from mesothelioma victims to the unimpaired.46 According to defendant companies, the aggregation of asbestos claims forced them to settle,
regardless of the strength of each case, “to avoid the possibility of substantial punitive damages awarded by sympathetic juries hearing
mesothelioma cases.”47 Thus, instead of aggressively contesting liability against claims of questionable merit, companies settled mass quan40. Id. at 1.
41. See, e.g., Landin et al., supra note 38, at 600 (noting that some overwhelmed courts
took “well-intentioned, but ill-fated, procedural shortcuts to usher the claims through the
system”); Wylie et al., supra note 26, at 2 (“[J]udges in asbestos litigation have all too often
processed massive caseloads ‘without regard to whether the claims themselves are based on
fraud, corrupt experts, perjury, and other things that would be deplored and persecuted
by the legal profession if done within other commercial fields.’” (quoting Dennis Jacobs,
The Secret Life of Judges, 75 FORDHAM L. REV. 2855, 2858 (2007))).
42. RAND 2005, supra note 22, at 28. Judges hoped that aggregating claims would
facilitate settlement discussions. Id.
43. See id. (noting that judges group cases together to encourage settlement even if the
claims include diverse locations and injuries); see also Castano v. Am. Tobacco Co., 84 F.3d
734, 746 (5th Cir. 1996) (“Class certification magnifies and strengthens the number of
unmeritorious claims . . . [and] creates insurmountable pressure on defendants to settle,
whereas individual trials would not.”).
44. Joseph P. Helm, III, Asbestos Litigation and the Proposed Administrative Remedy: Between
the Values of Individualism and Distributive Justice, 50 EMORY L.J. 631, 641 (2001) (citation and
internal quotation marks omitted).
45. Wylie et al., supra note 26, at 10–11.
46. Mass Torts Subcomm., Overview of Asbestos Claims Issues and Trends, 2007 AM. ACAD.
OF ACTUARIES 3.
47. Id.; see also In re Rhone-Poulenc Rorer Inc., 51 F.3d 1293, 1298 (7th Cir. 1995)
(explaining that when thousands of claimants file suit against a defendant, that defendant
can “easily be facing $25 billion in potential liability . . . [and] bankruptcy,” and thus,
“[t]hey will be under intense pressure to settle”); Edith H. Jones, Rough Justice in Mass
Future Claims: Should Bankruptcy Courts Direct Tort Reform?, 76 TEX. L. REV. 1695, 1696–97
(1998) (“[D]efendants’ liability, which should be a critical matter in the fashioning of a
just solution, becomes submerged beneath the overwhelming volume of claims and the
huge transactional costs of defending them.”).
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tities of cases.48 Responding opportunistically to their success,
plaintiffs’ counsel sought out more claimants, and subsequently, developed an entrepreneurial method for recruiting hundreds of
thousands of claimants through the use of mass screenings.49
Asbestos lawyers hired screening companies to recruit potential
claimants who, although not currently suffering from asbestos-related
injuries, exhibited symptoms of exposure.50 These screening companies used mobile x-ray vans to seek out potential clients in the parking
lots of hotels and restaurants.51 The purpose of these screenings was
to generate evidence—x-rays, pulmonary function tests, and medical
reports—to support claims of asbestos-related injuries.52 This entrepreneurial method of recruiting clients was wildly successful: From
1988 to 2006, mass screenings generated more than 90% of the approximately 585,000 nonmalignant claims filed with the Manville
Trust.53
B. The Supreme Court of the United States Requests an Administrative
Solution to the Asbestos Litigation Crisis
As asbestos cases continued to overwhelm certain jurisdictions,
United States Chief Justice William Rehnquist formed an Ad Hoc
Committee on Asbestos Litigation (“Ad Hoc Committee”) to examine
possible solutions to the asbestos litigation crisis.54 At the time of formation, the Chief Justice noted that “‘dockets in both federal and
state courts continue to grow; long delays are routine; trials are too
long; the same issues are litigated over and over; transaction costs exceed the victims’ recovery by nearly two to one; [and] exhaustion of
48. RAND 2005, supra note 22, at 1.
49. See id. at 23 (explaining that in their efforts to get more claimants, plaintiffs’ firms
engaged in mass screenings of asbestos workers).
50. Paul D. Carrington, Asbestos Lessons: The Consequences of Asbestos Litigation, 26 REV.
LITIG. 583, 604 (2007).
51. Victor E. Schwartz & Leah Lorber, A Letter to the Trial Judges of America: Help the True
Victims of Silica Injuries and Avoid Another Litigation Crisis, 28 AM. J. TRIAL ADVOC. 295, 309
(2004).
52. See, e.g., Lester Brickman, Disparities Between Asbestosis and Silicosis Claims Generated by
Litigation Screenings and Clinical Studies 29 CARDOZO L. REV. 513, 518 (2007) [hereinafter
Brickman, Disparities] (“The sole object of these [mass] screenings is to generate medical
reports to be used to support claims of asbestosis . . . .”); Judyth Pendell, Regulating AttorneyFunded Mass Medical Screenings: A Public Health Imperative?, 2005 AEI-BROOKINGS JOINT
CENTER FOR REG. STUD. 4 (“[A]ttorney-sponsored mass medical screenings became a primary tool for the recruitment of new claimants, particularly clients with little or no
impairment.”).
53. Brickman, Disparities, supra note 52, at 518–19.
54. O’Malley, supra note 35, at 1110.
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assets threatens and distorts the process . . . .’ ”55 Based on these conclusions, the Ad Hoc Committee recommended the adoption of an
administrative remedy for asbestos litigation.56 In Amchem Products,
Inc. v. Windsor,57 the Supreme Court reached the same conclusion:
“[A] nationwide administrative claims processing regime would provide the most secure, fair, and efficient means of compensating victims of asbestos exposure.”58 Two years later, the Supreme Court
again called for congressional action to solve the asbestos litigation
crisis.59
II.

CONGRESS ATTEMPTS TO CREATE A PRIVATELY FUNDED,
PUBLICALLY ADMINISTERED SYSTEM TO COMPENSATE
LEGITIMATE ASBESTOS-RELATED INJURIES

Although Congress has repeatedly attempted to create an administrative system to replace asbestos litigation, these efforts have not
succeeded.60 On May 22, 2003, Senator Orrin Hatch (R-UT) introduced the Fairness in Asbestos Injury Resolution Act, which the Senate Judiciary Committee approved by a roll call vote of ten to eight.61
When negotiations between the senators failed, however, Congress adjourned without voting on Senate Bill 1125.62 During the following
session, Senator Hatch reintroduced a revised version of the Act,
known as Senate Bill 2290, which increased claim values and included
an updated administrative structure.63 Again, negotiations stalled and
the 108th Congress adjourned without a floor vote on the bill.64
When Congress reconvened in January of 2005, Senator Arlen Specter
(R-PA) took control of the bill.65 Congress adjourned again, however,
without passing Senate Bill 852.66 The Fairness in Asbestos Injury Resolution Act of 2006,67 which Senator Specter introduced on May 26,
55. Id. at 1110–11 (internal citations omitted).
56. Id. at 1111.
57. 521 U.S. 591 (1997).
58. Id. at 628–29.
59. Ortiz v. Fibreboard Corp., 527 U.S. 815, 821 (1999) (“[Asbestos] litigation defies
customary judicial administration and calls for national legislation.”).
60. O’Malley, supra note 35, at 1120.
61. John W. Ames & Andrew D. Stosberg, The Fairness in Asbestos Injury Resolution Act of
2003: Is It a FAIR Act?, 22 AM. BANKR. INST. J. 26, 26 (2003).
62. O’Malley, supra note 35, at 1120–21. The FAIR Act would have established a $108
billion trust fund to resolve asbestos litigation. Id. at 1120.
63. Id. at 1121.
64. Id.
65. Id.
66. Id. at 1123.
67. Fairness in Asbestos Injury Resolution Act of 2006, S. 3274, 109th Cong. (2006).
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2006,68 represents Congress’s latest attempt to create an administrative method for fairly compensating victims of asbestos-related
injuries.69
Recognizing that the Supreme Court had requested a national
asbestos claims system,70 the FAIR Act purported to “create [a] legislative solution in the form of a national asbestos injury claims resolution
program to supersede all existing methods to compensate those injured by asbestos.”71 In addition to establishing a privately funded
and publically administered system to resolve asbestos claims,72 the
FAIR Act contained numerous provisions designed to prevent fraud
and the compensation of illegitimate claims.73 In response to Judge
Jack’s findings regarding silica litigation fraud,74 the FAIR Act’s draft-

68. Id.
69. Beth A. Dickhaus & Darrin N. Sacks, Recent Developments in Insurance Regulation, 42
TORT TRIAL & INS. PRAC. L.J. 571, 585 (2007); see also GovTrack: Text of S. 3274 [109th]—
FAIR Act of 2006, http://www.govtrack.us/congress/billtext.xpd?bill=s109-3274 (last visited Oct. 29, 2009) (noting that no member of Congress has pursued this bill since 2006).
70. S. 3274.
71. Id. § 2(a)(7).
72. Id. § 2(b)(1).
73. See, e.g., id. § 101(c)(1)(D) (establishing audit procedures “to assure the integrity of
the program”); id. § 101(c)(1)(H) (forbidding any attorney, physician, medical or diagnostic service provider, or laboratory who has engaged in fraudulent practices from participating in the program); id. § 101(c)(2) (establishing penalties for fraudulent statements or
practices); id. § 101(e) (establishing “audit and personnel review procedures for evaluating
the accuracy of eligibility recommendations of agency and contract personnel”); id.
§ 102(a)(3) (denying Advisory Committee membership to individuals who earned more
than 15% of their income from asbestos litigation in each of the five previous years); id.
§ 103(b) (denying Medical Advisory Committee membership to individuals who earned
more than 15% of their income from asbestos litigation in each of the five previous years);
id. § 104(c) (denying participation of organizations with a financial interest in the outcome of claims); id. § 104(e)(1) (capping attorneys’ fees at 5%); id. § 104(e)(2) (establishing punishments for exceeding the 5% cap on fees); id. § 105(c) (establishing
qualifications of physician panels); id. § 114(a)(2) (permitting the Administrator to require additional evidence to prove any claim); id. § 115(a) (establishing “Medical Evidence
Auditing Procedures”); id. § 115(b) (establishing “Review of Certified B-Readers”); id.
§ 121(b)(3) (creating procedures to ensure medical evidence is credible); id. § 121(c)
(creating procedures to ensure exposure evidence is credible); id. § 225(b)(3) (requiring
that preference be given to nonprofit organizations with asbestos-related experience for
contracts related to education, consultation, screening, and monitoring); id. § 225(c)(6)
(limiting compensation for medical screening services); id. § 401 (establishing penalties
for fraud and false information).
74. The Fairness in Asbestos Injury Resolution Act of 2006: Hearing on S. 3274 Before the S.
Comm. on the Judiciary, 109th Cong. 7 (2006) (statement of Governor John Engler, President, National Association of Manufacturers) (“Senate bill 3274 goes even further than the
earlier bill to prevent fraudulent claiming. We commend Federal Judge Janis Jack for exposing all of the fraud rampant in silica litigation . . . .”).
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ers incorporated anti-fraud provisions into the bill to prevent the
questionable practices that were occurring in the tort system.75
For example, the FAIR Act established an Office of Asbestos Disease Compensation (“Office”),76 which was headed by an Administrator whose duties included processing claims for asbestos-related
injuries and compensating eligible claimants on a no-fault basis and in
a nonadversarial manner.77 Significantly, the Administrator’s additional duties included “conducting such audits and additional oversight as necessary to assure the integrity of the program”78 and
“excluding evidence and disqualifying or debarring any attorney, physician, [or] provider of medical or diagnostic services . . . where the
Administrator determines that materially false, fraudulent, or fictitious statements or practices have been submitted or engaged in by
such individuals or entities.”79
Additionally, the Administrator would have received assistance
from multiple advisory committees and experienced physician panels.
The Advisory Committee on Asbestos Disease Compensation (“Advisory Committee”) would have consisted of members who had “experience or expertise in diagnosing asbestos-related diseases and
conditions, assessing asbestos exposure and health risks, [and] filing
asbestos claims.”80 Importantly, none of these individuals could have
served on the committee if he or she had, for each of the five years
before being appointed, earned more than 15% of his or her income
by serving as a consultant or an expert witness in asbestos litigation.81
The Administrator also would have established a Medical Advisory
Committee (“Medical Committee”) to provide expert advice on any
medical issues that may have arisen.82 Medical Committee members
also could not have earned more than 15% of their income from work
related to asbestos litigation during the previous five years.83 Finally,
75. See Patrick M. Hanlon, An Elegy for the FAIR Act, 12 CONN. INS. L.J. 517, 548–49
(2006) [hereinafter Hanlon, Elegy] (“[T]he FAIR Act emphasizes the importance of ensuring the quality of the data that are used in the administrative process . . . [which] is especially critical given the history of medical fraud and abuse that has made asbestos litigation
such a scandal.”).
76. S. 3274 § 101(a)(1).
77. Id. § 101(a)(2); id. § 101(c)(1)(A).
78. Id. § 101(c)(1)(D).
79. Id. § 101(c)(1)(H). For each infraction, the Administrator may have imposed a
fine of $10,000 on anyone submitting “a materially false, fraudulent, or fictitious statement
or practice under this Act.” Id. § 101(c)(2).
80. Id. § 102(a)(3).
81. Id. For members’ duties, see id. § 102(b).
82. Id. § 103(a).
83. Id. § 103(b).

\\server05\productn\M\MLR\69-1\MLR112.txt

2009]

unknown

ASBESTOS FRAUD SHOULD LEAD

Seq: 10

TO

FAIRNESS

25-NOV-09

9:54

171

to assist with making medical determinations for each claimant, the
Administrator would have appointed Physician Panels.84 To qualify
for admittance on a Physician Panel, the physician needed to be licensed in any state and had to have “experience and competency in
diagnosing asbestos-related diseases.”85 While individuals appointed
to a Physician Panel would have been reasonably compensated for
their services,86 they also could not have earned more than 15% of
their income during the previous five years “as an employee of a participating defendant or insurer or a law firm representing any party in
asbestos litigation or as a consultant or expert witness in matters related to asbestos litigation.”87
In addition to establishing advisory panels, the FAIR Act also included specific provisions designed to prevent—and punish—the
types of fraudulent statements and practices exposed by Judge Jack.
For example, the FAIR Act gave the Administrator authority to establish a claimant assistance program consisting of labor organizations
and other entities, but these organizations were prohibited from having any financial interest in the outcome of the claims.88 By eliminating financial incentives, organizations participating in the claimant
assistance program would not have had illicit motivation to seek out
claimants or embellish their numbers or injuries.
Additionally, while claimants were permitted to have legal assistance, the Administrator would have created a roster of qualified attorneys who had agreed to provide pro bono services.89 Any attorney
involved in the administrative claims process would have been forbidden from recovering fees above 5% of the claimant’s award.90 Importantly, attorneys who recovered more than the 5% fee cap would have
been fined up to $5000 or twice the amount of the inappropriate fee
charged.91
The FAIR Act specifically attempted to thwart the filing of illegitimate claims and fraudulent medical evidence. First, claimants seeking
compensation under the FAIR Act needed to provide their name, Social Security number, and “a description of any prior or pending civil
84. Id. § 105(a).
85. Id. § 105(c). Additionally, to be eligible, a physician needed to be board-certified
in pulmonary medicine, occupational medicine, internal medicine, oncology, or pathology. Id. § 105(c)(2).
86. Id. § 105(e).
87. Id. § 105(c)(3).
88. Id. § 104(c).
89. Id. § 104(d)(2).
90. Id. § 104(e)(1).
91. Id. § 104(e)(2).
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action or other claim brought by the claimant for asbestos-related injury or any other pulmonary, parenchymal, or pleural injury.”92 By
requiring this information, Congress most likely wanted the Administrator to ensure that claimants had not already recovered for asbestosor silica-related injuries through other means. In addition, the Administrator would have developed auditing procedures to evaluate
medical evidence submitted by claimants.93 If, through these audits,
the Administrator determined that a physician’s or medical facility’s
evidence was inconsistent with prevailing practices, all evidence from
such a physician or facility would have been unacceptable.94 Further,
the Administrator would have maintained a list of acceptable, certified
B-readers to independently review incoming x-rays.95 Finally, anyone
submitting false information could be punished under 18 U.S.C.
§ 135196 or Section 101(c)(2) of the FAIR Act.97

92. Id. § 113(c).
93. Id. § 115(a)(1).
94. Id. § 115(a)(2)(A).
95. Id. § 115(b). A B-reader is a physician who has demonstrated proficiency in evaluating and interpreting chest x-rays for pneumoconiosis and other diseases. 42 C.F.R.
§ 37.51(b) (2008).
96. The FAIR Act would amend Chapter 63 of Title 18, United States Code, by adding
the following:
§ 1351. Fraud and false statements in connection with participation in Asbestos
Injury Claims Resolution Fund:
(a) Fraud Relating to Asbestos Injury Claims Resolution Fund.—Whoever knowingly and willfully executes, or attempts to execute, a scheme or artifice to defraud the Office of Asbestos Disease Compensation or the Asbestos Insurers
Commission under title II of the Fairness in Asbestos Injury Resolution Act of
2006 shall be fined under this title or imprisoned not more than 20 years, or
both.
(b) False Statement Relating to Asbestos Injury Claims Resolution Fund.—(1) . . .
It shall be unlawful for any person, in any matter involving the Office of Asbestos
Disease Compensation or the Asbestos Insurers Commission, to knowingly and
willfully—(A) falsify, conceal, or cover up by any trick, scheme, or device a material fact; (B) make any materially false, fictitious, or fraudulent statement or representation; or (C) make or use any false writing or document knowing the same
to contain any materially false, fictitious, or fraudulent statement or entry, in connection with the award of a claim or the determination of a participant’s payment
obligation under title I or II of the Fairness in Asbestos Injury Resolution Act of
2006. (2) . . . A person who violates this subsection shall be fined under this title
or imprisoned not more than 10 years, or both.
S. 3274 § 401(a).
97. E.g., § 115(c)(4); id. § 121(c)(6).
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III. THE INTERSECTION OF ASBESTOS AND SILICA LITIGATION: THE
SILICA MULTIDISTRICT LITIGATION’S ABILITY TO AFFECT
ASBESTOS REFORM
When the United States Senate began considering an administrative solution to asbestos litigation, which would have limited compensation for unimpaired asbestosis claims to medical monitoring
expenses, the asbestos bar began to shift focus.98 Plaintiffs’ firms and
screening companies that had previously focused on asbestos began to
recruit silicosis claimants “to keep the asbestos-litigation gravy train
alive.”99 When the asbestos bar shifted to silicosis claims, it was able to
use some of the same techniques that had proved to be advantageous
in asbestos litigation.100 For example, filing numerous silicosis claims
could (1) overwhelm courts, thus enabling plaintiffs’ counsel to settle
claims without close supervision; (2) pressure courts to adopt innovative means of processing cases; and (3) prevent defendants from vigorously defending cases because of financial pressure to settle.101
As the FAIR Act was pending in the Senate, however, a federal
judge from the Southern District of Texas handed down a decision
that would profoundly affect the field of mass torts, including asbestos
litigation.102 That decision, made by Judge Janis Graham Jack in the
Silica Multidistrict Litigation (“Silica MDL”), has been one of the most
dramatic events to catalyze asbestos reform.103 By uncovering a fraudulent operation to manufacture silicosis diagnoses, Judge Jack ex98. Hanlon & Smetak, supra note 28, at 595 (“[T]he pendency of the FAIR Act has had
a depressing effect on the recruitment of new non-malignant [asbestos] cases . . . [because] a change in law could render the investment in new cases useless.”).
99. Andrew P. Morriss & Susan E. Dudley, Defining What to Regulate: Silica and the Problem of Regulatory Classification, 58 ADMIN. L. REV. 269, 344 (2006) (citations and internal
quotation marks omitted).
100. Id. at 349–51.
101. Id.
102. See Mark A. Behrens & Phil Goldberg, The Asbestos Litigation Crisis: The Tide Appears
to be Turning, 12 CONN. INS. L.J. 477, 493 (2006) [hereinafter Behrens & Goldberg, The
Tide] (“Another event that should accelerate the demise of mass screenings was a watershed ruling in June 2005 by the manager of the federal silica multi-district litigation
docket, U.S. District Judge Janis Graham Jack of the Southern District of Texas.”); David J.
Kahne, Curbing the Abuser, Not the Abuse: A Call for Greater Professional Accountability and
Stricter Ethical Guidelines for Class Action Lawyers, 19 GEO. J. LEGAL ETHICS 741, 741 (2006)
(noting that Judge Jack’s opinion “has been heralded as a major step in the movement for
class action reform”); Mass Torts Subcomm., Overview of Asbestos Claims Issues and Trends,
2007 AM. ACAD. OF ACTUARIES 6 (noting that Judge Jack’s decision will likely lead to increased medical evidentiary standards for both silica and asbestos claims).
103. Frederick C. Dunbar et al., Forecasting Asbestos Liability After Recent Bankruptcy Decisions: How Forecasts Must Adjust for Changes in the Tort System, 2006 NERA ECON. CONSULTING
2.
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posed lawyers, diagnosing doctors, and screening companies that had
also been key players in asbestos litigation.104
A. The Formation of the Silica MDL: One Step Closer to Exposing
Fraudulently Generated Silicosis Diagnoses
On September 4, 2003, the Judicial Panel on Multidistrict Litigation centralized over 10,000 silicosis claims pursuant to 28 U.S.C.
§ 1407 in the Southern District of Texas with Judge Jack.105 Although
Judge Jack surmised that the court lacked subject matter jurisdiction
over the MDL cases, she allowed the defendants to conduct discovery
on fraudulent misjoinder.106 On January 23, 2004, Judge Jack ordered the parties to complete “Fact Sheets” to assist the court in determining its subject matter jurisdiction.107 As such, each plaintiff
needed to submit detailed medical information about his or her alleged exposure to silica dust and injuries.108
When the plaintiffs submitted their Facts Sheets, the court noticed that twelve doctors had diagnosed approximately 9000 claimants.109 These doctors were not the plaintiffs’ treating physicians, but
rather were affiliated with a handful of law firms and screening companies.110 On October 29, 2004, the defendants deposed Dr. George
Martindale, who had diagnosed 3617 plaintiffs with silicosis.111 Each
of Dr. Martindale’s medical reports contained the following language:
“On the basis of the medical history review, which is inclusive of a
significant occupational exposure to silica dust, physical exam and the
chest radiograph, the diagnosis of silicosis is established within a reasonable degree of medical certainty.”112 Despite this clear language,
during his deposition, Dr. Martindale testified that he did not intend
104. Id. Because silica litigation involves the same mode of operation as asbestos litigation, Judge Jack’s decision will most likely “apply with equal force to asbestos litigation.”
Lester Brickman, On the Applicability of the Silica MDL Proceeding to Asbestos Litigation, 12
CONN. INS. L.J. 289, 290 (2006) [hereinafter Brickman, Applicability].
105. In re Silica Prods. Liab. Litig., 398 F. Supp. 2d 563, 573 (S.D. Tex. 2005); see also In
re Silica Prods. Liab. Litig., 280 F. Supp. 2d 1381, 1383 (J.P.M.L. 2003) (transferring silica
cases to Judge Jack).
106. In re Silica, 398 F. Supp. 2d at 574–75.
107. Id. at 575–76.
108. Id. at 576. Judge Jack did not limit discovery to these Fact Sheets, but rather allowed discovery to proceed at the parties’ discretion. Id.
109. Id. at 580. The doctors are the following: Dr. Robert Altmeyer, Dr. James Ballard,
Dr. Kevin Cooper, Dr. Todd Coulter, Dr. Andrew Harron, Dr. Ray Harron, Dr. Glynn Hilbun, Dr. Richard Levine, Dr. Barry Levy, Dr. George Martindale, Dr. W. Allen Oaks, and
Dr. Jay Segarra. Id. at 580 n.24.
110. Id. at 580.
111. Id. at 581.
112. Id.
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to diagnose any plaintiff with silicosis, he did not speak with a single
plaintiff during their screenings, and he did not even know the criteria for diagnosing silicosis.113 Expressing concern over Dr. Martindale’s withdrawal of his diagnoses, the court proposed Daubert114
hearings and court depositions for the remaining diagnosing doctors
and screening companies.115 Judge Jack chose to conduct Daubert
hearings because they “were the most efficient and effective way to
allow the Defendants to depose the doctors (as is their right under the
Federal Rules of Civil Procedure), while providing direct Court supervision over the proceedings . . . .”116 Her decision to conduct Daubert
hearings was unprecedented for this stage of a mass tort
proceeding.117
B. The Unprecedented Decision to Conduct Daubert Hearings Leads to
Discoveries About the Prevalence of Fraud in Silica and
Asbestos Litigation
Judge Jack conducted Daubert hearings and court depositions
before deciding whether the court had subject matter jurisdiction because such hearings were potentially relevant to the court’s jurisdiction and were warranted by the defendants’ motion for sanctions.118
In performing a Daubert analysis, Judge Jack focused on the accepted
criteria for diagnosing silicosis: (1) sufficient exposure to silica dust
and an appropriate latency period; (2) radiographic evidence of silicosis; and (3) the elimination of alternative causes of the radiographic
findings.119 As a former nurse,120 Judge Jack found that the diagnosing doctors’ adherence to these criteria “ranged from questionable to
abysmal.”121 The significance of these findings is not limited to silica
litigation; Judge Jack’s opinion is valuable because of the potential
113. Id. at 581–82.
114. See Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 592–94 (1993) (establishing
criteria to determine the reliability of scientific expert testimony).
115. In re Silica, 398 F. Supp. 2d at 584. Despite the upcoming Daubert hearings, the
court allowed the defendants to conduct previously scheduled depositions of Dr. Glynn
Hilbun and Dr. Kevin Cooper, who each emphasized that they did not diagnose any of the
plaintiffs with silicosis, but rather signed forms provided by the screening company without
first reviewing them. Id. at 587–88.
116. Id. at 585–86.
117. See Wylie et al., supra note 26, at 12 (explaining that the testimony and cross-examination of diagnosing doctors and screening companies in court was previously unheard of
in mass tort proceedings).
118. In re Silica, 398 F. Supp. 2d at 579–80.
119. Id. at 622.
120. David Maron & Walker W. (Bill) Jones, Taming an Elephant: A Closer Look at Mass
Tort Screening and the Impact of Mississippi Tort Reforms, 26 MISS. C. L. REV. 253, 275 (2007).
121. In re Silica, 398 F. Supp. 2d at 622.
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exposure of fraud in the asbestos arena.122 Most importantly, the exact lawyers, doctors, and screening companies from the silica litigation
had been using the same techniques to generate nonmalignant asbestos claims; thus, the legitimacy of most asbestos claims filed in the tort
system within the last few decades is questionable.123
Regarding the first criterion for diagnosing silicosis, Judge Jack
concluded that the diagnosing doctors’ testimony could not be admitted under Daubert because almost all of the plaintiffs’ diagnoses failed
to satisfy the minimum medically acceptable standard for diagnosing
silicosis.124 According to one doctor, “it is not appropriate for anyone
other than the physician or an agent of the physician to take the exposure and past medical history.”125 In this case, Judge Jack observed
that people with no medical training obtained plaintiffs’ exposure histories and that there were significant financial incentives to find adequate exposure.126 For example, Dr. Barry Levy, a physician involved
in both asbestos and silica litigation,127 diagnosed approximately 1389
plaintiffs in the Silica MDL without taking their occupational or medical histories, performing their B-reads, physically examining them, or
even speaking to them or their primary care physicians.128 Judge Jack
summarized the findings of Dr. Levy, who had performed 1239 evaluations in seventy-two hours: “Dr. Levy worked at a break-neck pace
which apparently led to some errors; and his exposure and medical
122. Roger Parloff, Diagnosing for Dollars, FORTUNE, June 13, 2005, at 96 (“The real importance of [Judge Jack’s] proceedings, however, is not what they reveal about possible
fraud in silica litigation but what they suggest about a possible fraud of vastly greater
dimensions. It’s one that may have been afflicting asbestos litigation for almost 20
years . . . .”).
123. See Brickman, Applicability, supra note 104, at 290 (“Because silicosis litigation involves the same modus operandi as entrepreneurially generated nonmalignant asbestos
litigation, the same screening enterprises, B Readers, diagnosing doctors, and law firms, it
is reasonable to conclude that Judge Jack’s findings apply with equal force to asbestos
litigation.”); see also Frederick C. Dunbar et al., Institutional Response to Tort System
Breakdown: Asbestos Enters a New Phase 9 (July 21, 2006) (unpublished working paper,
on file with the Maryland Law Review) [hereinafter Dunbar, Institutional Response] (noting
that, following Judge Jack’s decision, both the Manville Trust and the Eagle Picher Trust
stopped accepting asbestos claims where the medical support was provided by the doctors
or screening companies challenged in the Silica MDL).
124. In re Silica, 398 F. Supp. 2d at 625.
125. Id. at 623.
126. Id. at 622. Often, screening companies only received payment for providing the
firm with positive diagnoses. Id. at 601, 628.
127. See Mark A. Behrens, What’s New in Asbestos Litigation?, 28 REV. LITIG. 501, 520 n.107
(2009) (noting that several asbestos trusts have banned Dr. Levy’s medical reports after his
involvement in the Silica MDL).
128. In re Silica, 398 F. Supp. 2d at 611. In fact, in the eighteen years prior to the Silica
MDL, Dr. Levy was not acting as a treating physician, but rather had been consulting in
litigation for plaintiffs’ firms for $600 per hour. Id. at 611 n.83.
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histories were not taken by medically-trained people and were below
the standard set by his [own] writings and his ‘protocol.’”129 To
Judge Jack, “it [wa]s clear that Dr. Levy had an agenda: diagnose silicosis and nothing else.”130
Additionally, plaintiffs’ diagnosing doctors did not satisfy the second factor required to establish a medically acceptable silicosis diagnosis. Judge Jack concluded that the plaintiffs’ radiographic
evidence—positive B-reads—were insufficient to establish silicosis diagnoses according to conventional medical standards.131 Even assuming that the diagnosing doctors’ B-reads were unbiased and reliable,
which is highly unlikely,132 Judge Jack declined to accept a positive Bread as radiographic evidence of silicosis for three reasons.133 First,
the B-reader system was not established for litigation purposes; thus,
one positive B-read alone should not have been sufficient to diagnose
silicosis.134 Second, plaintiffs’ B-readers relied on the ILO classification system, but the ILO guidelines were never intended for application in a legal setting and were not supposed to be used to diagnose
disease.135 Finally, to reduce reader bias, B-readers should not know
either the patient’s exposure history or the suspected disease.136 In
the plaintiffs’ cases, however, the diagnosing doctors had incentives to
find silicosis.137
Regarding the last criterion for diagnosing silicosis—that plaintiffs’ diagnosing doctors eliminate alternative causes of positive Breads—Judge Jack found that “[i]n almost all of the MDL cases, the
challenged diagnosing doctors simply ignored this final criterion . . . .”138 In fact, at least one diagnosing doctor seemed willing to
change a claimant’s diagnosis depending on whether the firm wanted
to file an asbestos or silicosis claim. This doctor, Ray Harron, had not
practiced medicine for approximately ten years, but rather had
worked exclusively for plaintiffs’ lawyers and the screening company
129. Id. at 611–12, 615. Dr. Levy spent approximately four minutes per evaluation. Id.
at 611–12.
130. Id. at 615.
131. Id. at 625.
132. See, e.g., id. at 629 (explaining why B-reads for silica and asbestos litigation are unreliable); Owens Corning v. Credit Suisse First Boston, 322 B.R. 719, 723 (D. Del. 2005)
(“Certain pro-plaintiff B-readers [are] so biased that their readings [are] simply
unreliable.”).
133. In re Silica, 398 F. Supp. 2d at 625.
134. Id. at 626.
135. Id.
136. Id. at 626–27.
137. Id. at 627–28.
138. Id. at 629–30.
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N & M, Inc.139 During Dr. Harron’s deposition, the court learned
that he had failed to write, dictate, read, or personally sign any of the
approximately 6350 medical reports he had issued.140 Dr. Harron explained that his silicosis diagnoses, reported to be “within a reasonable degree of medical certainty,” were not actual medical diagnoses,
but instead merely set forth a legal standard.141 Most importantly, the
defendants presented evidence that prior to the Silica MDL, Dr. Harron had read 1807 x-rays as consistent with asbestosis but not silicosis;
however, when reexamining the same x-rays for the silica litigation, he
found silicosis in every case.142 When presented with evidence of such
reversals, Dr. Harron refused to continue with his deposition until he
could consult with his own attorney.143
As such, after conducting Daubert hearings and court depositions,
Judge Jack concluded that the plaintiffs’ silicosis diagnoses were “manufactured on an assembly line.”144 She exposed the fact that plaintiffs’
lawyers, doctors, and screening companies had concocted a scheme to
manufacture diagnoses for money.145 For example, Judge Jack noted
that N & M, Inc., a Mississippi screening company that generated silicosis diagnoses for approximately 6757 plaintiffs, “found 400 times
more silicosis cases than the Mayo Clinic (which sees 250,000 patients
a year) treated during the same [two year] period.”146 Additionally,
among the 6757 claimants generated by N & M, Inc., over 4000 of
them had previously filed asbestosis claims,147 even though having
both asbestosis and silicosis is a “clinical rarity.”148
Although Judge Jack recognized that plaintiffs’ lawyers “had to
know that he or she was filing at least some claims that falsely alleged
silicosis,” the court could neither sanction these lawyers nor rule on
the admissibility of the diagnosing doctors’ testimony because it
139. Id. at 603–04.
140. Id. at 605. Dr. Andrew Harron, Ray Harron’s son, testified in his own deposition
that he used the same diagnosing procedure as his father. Id. at 609.
141. Id. at 604.
142. Id. at 607–08. According to one of plaintiffs’ other experts, intra-reader variability
simply cannot explain Dr. Harron’s reversal rate. Id. at 608.
143. Id. at 607.
144. Id. at 633.
145. Id. at 635 (“The record does not reveal who originally devised this scheme, but it is
clear that the lawyers, doctors and screening companies were all willing participants.”).
146. Id. at 603.
147. Id.
148. Id. at 595; see also Asbestos: Mixed Dust and FELA Issues: Hearing Before the S. Comm. on
the Judiciary, 109th Cong. 16 (2005) (statement of Dr. Paul Epstein, Chief, Pulmonary and
Critical Care Medicine) (“[I]t is my professional opinion that the dual occurrence of asbestosis and silicosis is a clinical rarity.”).
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lacked subject matter jurisdiction over almost all of the MDL cases.149
Judge Jack disclosed the findings, however, so that state courts would
not have to re-conduct Daubert hearings on the same challenged doctors and their diagnoses.150 Overall, Judge Jack revealed that the silicosis epidemic was largely a result of misdiagnosis.151 Most
importantly, Judge Jack’s decision revealed that the lawyers, diagnosing doctors, and screening companies that presented the fraudulent
silicosis diagnoses had engaged in identical practices to generate
claims for asbestos litigation.152
IV.

THE DEMISE OF THE FAIRNESS IN ASBESTOS INJURY RESOLUTION
ACT: THE SENATE’S INABILITY TO PREDICT THE NUMBER OF
FUTURE ASBESTOS CLAIMS IMPEDES NEGOTIATIONS

Despite Judge Jack’s extensive findings of fraud in silica and asbestos litigation, the 109th Congress adjourned without passing the
FAIR Act.153 Much of the debate surrounding the FAIR Act focused
on whether the administrative trust fund (“Fund”) would have been
sufficient to compensate claimants fairly and effectively without becoming insolvent.154 Some opponents of the FAIR Act feared that the
administrative remedy “would replace the current broken litigation
system for asbestos injury claims with a complicated, expensive, and
ultimately unsustainable entitlement program.”155
A. Disagreements over the Structure of the FAIR Act Impede
Negotiations
Numerous issues impeded negotiations over the FAIR Act, which
ultimately prevented Congress from enacting the bill. First, the FAIR
Act’s drafters struggled to balance administrative efficiency and pro149. In re Silica, 398 F. Supp. 2d at 636–37. The District Court of the Southern District
of Texas had jurisdiction over one matter, and in that case, Judge Jack sanctioned the law
firm of O’Quinn, Laminack & Pirtle for multiplying the proceedings “‘unreasonably and
vexatiously.’” Id. at 673–74, 676 (quoting 28 U.S.C. § 1927 (2006)); see also 28 U.S.C.
§ 1927 (“Any attorney . . . who so multiplies the proceedings in any case unreasonably and
vexatiously may be required by the court to satisfy personally the excess costs, expenses,
and attorneys’ fees reasonably incurred because of such conduct.”).
150. In re Silica, 398 F. Supp. 2d at 637.
151. Id. at 632.
152. Brickman, Applicability, supra note 104, at 299; see also In re Silica, 398 F. Supp. 2d at
629 (“[E]vidence of the unreliability of the B-reads performed for this MDL is matched by
evidence of the unreliability of B-reads in asbestos litigation.”).
153. Katherine Dirks, Note, Ethical Rules of Conduct in the Settlement of Mass Torts: A Proposal to Revise Rule 1.8 (G), 83 N.Y.U. L. REV. 501, 507 n.41 (2008).
154. 152 CONG. REC. S875, 883 (daily ed. Feb. 9, 2006) (statement of Sen. Cornyn).
155. 152 CONG. REC. S781, 838 (daily ed. Feb. 8, 2006) (statement of Sen. Cornyn).
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gram integrity.156 While a highly adversarial program would increase
program integrity by ensuring that only deserving claimants are compensated, it also would escalate transaction costs and delays, and thus
decrease efficiency.157 Specifically, the drafters disagreed on the best
means to determine eligibility for claimants and claim values.158 Opponents of the FAIR Act believed that the bill’s medical criteria would
compensate too many people without asbestos-related injuries.159 For
example, the biggest dispute was whether to allow victims of lung cancer without asbestosis to recover.160
Next, the parties disagreed over the best method of transitioning
from the tort system to the FAIR Act’s administrative system.161 Defendant companies feared that if pending claims were permitted to
remain in the tort system, attorneys would try to litigate as many
claims as possible.162 Conversely, some were concerned that if the
FAIR Act immediately preempted the tort system, the time and resources of claimants who were far into the litigation process would be
wasted.163
Additionally, defendant companies and their insurers struggled
to agree on how to allocate the program’s costs, which were estimated
to be approximately $140 billion.164 Each defendant’s contribution
depended on an allocation formula that took the following factors
into account: (1) whether the company was in bankruptcy; (2) the size
of the company’s gross revenue; and (3) the amount of the company’s
previous asbestos expenditures.165 Critics argued that the FAIR Act’s
funding structure favored large companies over smaller ones and that
it resulted in “takings” of insurance companies’ assets.166

156. Hanlon & Smetak, supra note 28, at 588.
157. Hanlon, Elegy, supra note 75, at 547.
158. Hanlon & Smetak, supra note 28, at 588.
159. 152 CONG. REC. S875, 897 (daily ed. Feb. 9, 2006) (statement of Sen. Cornyn).
160. Patrick M. Hanlon, Federal Asbestos Legislation: Wrestling with the Medical Issues, 15 J.L.
& POL’Y 1171, 1195–96 (2007) [hereinafter Hanlon, Wrestling].
161. Hanlon & Smetak, supra note 28, at 590–91.
162. Id. at 590.
163. 152 CONG. REC. S875, 887 (daily ed. Feb. 9, 2006) (statement of Sen. Durbin).
164. Hanlon & Smetak, supra note 28, at 590.
165. Hanlon, Wrestling, supra note 160, at 1185.
166. Deborah R. Hensler, Asbestos Litigation in the United States: Triumph and Failure of the
Civil Justice System, 12 CONN. INS. L.J. 255, 276–77 (2006) (citation and internal quotation
marks omitted).
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B. The FAIR Act Fails to Survive a Technical Budget Point of Order
Because Its Drafters Could Not Provide Assurance that the
Fund Would Remain Solvent
The FAIR Act ultimately failed because the Congressional Budget
Office (“CBO”) could not confidently predict the number of future
asbestos claims that would require compensation, and thus the bill’s
drafters could not assure skeptics that the Fund would remain solvent.167 Some believed that establishing the Fund would decrease the
number of asbestos claims filed, while others argued that the opposite
would occur.168 Regardless, the drafters needed a way to accurately
estimate the number of legitimate claims that would be filed in order
to predict the total cost of the administrative system. As a result, the
CBO used claim rates in the tort system and other asbestos trusts as a
basis for projecting claims against the Fund.169 Based on these models, the CBO predicted that the Fund would need approximately $140
billion to fully compensate all legitimate claimants.170 Whereas some
trusted that $140 billion would suffice and some did not,171 most
agreed that “the cost of an administrative system is inherently uncertain.”172 In fact, the CBO even reported that predicting the administrative system’s cost was impossible because no one could guess the
volume of future claims, the percentage of legitimate claims, or the
pace of such approvals.173
As such, although one of the main purposes of the FAIR Act was
to provide certainty to defendant companies about their total asbestos
expenditures, the possibility that the Fund would become insolvent—
thus requiring the parties to return to the tort system—defeated this
167. See Hanlon & Smetak, supra note 28, at 589 (explaining that one of the principal
issues plaguing the drafters concerned the cost of the administrative system).
168. 152 CONG. REC. S875, 881 (daily ed. Feb. 9, 2006) (statement of Sen. Bennett).
The General Accounting Office has found that, in general, creating a trust fund results in
twice as many claims as that predicted at the time of its creation. Id. at 882.
169. Hanlon, Elegy, supra note 75, at 568.
170. 152 CONG. REC. S1135, 1141 (daily ed. Feb. 14, 2006) (statement of Sen. Specter).
Specifically, the CBO predicted that the Fund would require between $120 and $150 billion. Id. at 1142 (statement of Sen. Feinstein). Although the CBO’s estimated range implied that there was some risk that the Fund could become insolvent, the CBO did not
predict a short term collapse. Hanlon, Elegy, supra note 75, at 566.
171. 152 CONG. REC. S875, 881 (daily ed. Feb. 9, 2006) (statement of Sen. Bennett).
172. Hanlon & Smetak, supra note 28, at 589; see also 152 CONG. REC. S875, 886 (daily ed.
Feb. 9, 2006) (statement of Sen. Durbin) (noting that predicting the funding required for
this administrative system was nearly impossible because the cost needed to be estimated
over a fifty-year period).
173. 152 CONG. REC. S875, 889 (daily ed. Feb. 9, 2006) (statement of Sen. Specter).
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purpose.174 The FAIR Act’s drafters wanted to provide defendant
companies with certainty about their asbestos costs to promote financing of business operations and to reassure shareholders.175 But when
the drafters claimed that it was nearly impossible to predict the total
required funding, the defendant companies and their insurers began
to withdraw their support of the bill.176 These companies and their
insurers were reluctant to spend $140 billion only to end up back in
the tort system177 and were unwilling to write a blank check to cover
the system’s costs.178 Indeed, Senator Durbin (D-IL) argued that the
$140 billion estimate “falls short of the kind of certitude that we
should have before we close down the court system of America to hundreds of thousands of injured people and their families.”179
In addition to the concern over lack of certainty, the budget issue
ultimately doomed the FAIR Act by causing a political rift between
Democrats and Republicans.180 Attempting to create a privately
funded, no-fault administrative compensation program caused political tension because Democrats and Republicans take opposite positions regarding tort reform.181 For example, Senator Orrin Hatch (RUT) described the level of political compromise necessary to enact a
legislative solution to the asbestos litigation crisis: “[C]onservatives . . .
[must] turn a deaf ear to many of [their] traditional supporters and
endorse the very kind of Federal structure against which [they] battle
daily . . . [a]nd liberals . . . [must] say enough is enough to one of
their most important and influential constituencies.”182 Ultimately,
the FAIR Act failed because of lack of support from conservative
Republicans.183 Conservative senators feared that, should the Fund
become insolvent, a future Congress would not allow the program to
sunset; instead, it would use taxpayers’ money to compensate remain174. Patrick M. Hanlon, The Proposed Federal Asbestos Trust Fund, SK040 A.L.I.-A.B.A. 479,
501 (2004).
175. Hanlon & Smetak, supra note 28, at 589.
176. Hanlon, Elegy, supra note 75, at 568–69.
177. Id. at 578–79.
178. Patrick M. Hanlon, Asbestos Legislation: The FAIR Act Two Years On, 1 PRATT’S J.
BANKR. L. 207, 237 (2005).
179. 152 CONG. REC. S875, 886 (daily ed. Feb. 9, 2006) (statement of Sen. Durbin).
180. Hanlon, Elegy, supra note 75, at 519.
181. Robert S. Peck, Violating the Inviolate: Caps on Damages and the Right to Trial by Jury, 31
U. DAYTON L. REV. 307, 308 n.5 (2006). Tort reform divides the political parties because
Democrats generally represent the interests of unions and trial lawyers, whereas Republicans usually align with the interests of businesses and professionals. Anthony Champagne,
Tort Reform and Judicial Selection, 38 LOY. L.A. L. REV. 1483, 1491 (2005).
182. 152 CONG. REC. S1135, 1151 (daily ed. Feb. 14, 2006) (statement of Sen. Hatch).
183. Hanlon, Wrestling, supra note 160, at 1177.
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ing claimants.184 Thus, they wanted to avoid enacting a bill that would
become a federal financial responsibility.185
V.

JUDGE JACK’S FINDINGS IN THE SILICA MDL AND THE EVENTS THAT
RESULTED INDICATE THAT THE FAIR ACT’S FRAMERS
OVERESTIMATED THE NUMBER OF CLAIMS THE ADMINISTRATIVE
SYSTEM WOULD RECEIVE

The results from the Silica MDL should significantly affect asbestos reform because, by conducting Daubert hearings and court depositions, Judge Jack exposed the prevalence of fraud in both silica and
asbestos litigation. Based on the prevalence of fraud uncovered, it is
reasonable to conclude that the number of asbestos claims filed in the
tort system is greatly inflated due to illegitimate claims.186 The CBO,
as well as the senators who supported the FAIR Act, failed to recognize
the importance of Judge Jack’s findings.187 Instead, they used the tort
and bankruptcy-trust systems, which have grossly inflated asbestos filings, to predict how many claims would be filed with the Fund.188 Because of this oversight, supporters of the bill were unable to reassure
its opponents that the $140 billion estimate was sufficient to cover the
administrative system’s costs.
A. Judge Jack’s Findings in the Silica MDL Demonstrate that the Total
Number of Asbestos Claims in the Tort System Is Grossly
Inflated Due to Fraud
Even though Judge Jack’s opinion focused on silicosis claims, the
fraud uncovered during the Daubert hearings and court depositions
applies to asbestos litigation as well. Judge Jack’s findings directly affect asbestos-related claims because such claims are generated by the
same mass screening procedures discussed in the Silica MDL189 and
the retreaded asbestosis claims were based on unfounded medical di-

184. Id. at 1186–87; see also The Fairness in Asbestos Injury Resolution Act of 2006: Hearing on
S. 3274 Before the S. Comm. on the Judiciary, 109th Cong. 15 (2006) (statement of Douglas
Holtz-Eakin, Director, Council on Foreign Relations) (arguing that a future Congress will
most likely use taxpayer dollars to bail out the Fund instead of reducing claim values or
heightening eligibility standards).
185. Hanlon, Wrestling, supra note 160, at 1177–78.
186. See infra Part V.A.
187. See infra Part V.B.
188. See infra Part V.B.
189. See infra Part V.A.1.
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agnoses.190 Additionally, more recent events have substantiated Judge
Jack’s findings with respect to asbestos litigation.191
1. The Number of Legitimate Asbestos Claims Is Probably Inflated
Because Most Claims in the Tort System Were Generated
Through Mass Screenings
While evaluating the legitimacy of more than 10,000 silicosis
claims in her courtroom, Judge Jack noted that, according to statistics
from the National Institute for Occupational Safety and Health, one
could anticipate approximately eight new silicosis diagnoses per year
in Mississippi.192 From 2002 to 2004, however, about 20,479 plaintiffs
filed silicosis claims in Mississippi, which is “over five times greater
than the total number of silicosis cases one would expect over the
same period in the entire United States.”193 According to Judge Jack,
the number of silicosis claims defied “all medical knowledge and
logic.”194 Instead, the enormous discrepancy occurred because of
mass screenings, which dramatically inflate the number of claims beyond what is scientifically expected.195
Judge Jack’s findings about the fraudulent nature of mass screenings implicates many asbestos claims because the methods of diagnosing asbestosis and silicosis through these screenings are virtually
identical.196 In fact, the plaintiffs’ firms involved in the Silica MDL
190. See infra Part V.A.2.
191. See infra Part V.A.3.
192. In re Silica Prods. Liab. Litig., 398 F. Supp. 2d 563, 571 (S.D. Tex. 2005).
193. Id. at 572 (emphasis added).
194. Id. at 620. Judge Jack concluded the following:
In short, this appears to be a phantom epidemic, unnoticed by everyone other
than those enmeshed in the legal system: the defendants, who have already spent
millions of dollars defending these suits; the plaintiffs, who have been told that
they are suffering from an incurable, irreversible and potentially fatal disease; and
the courts, who must determine whether they are being faced with the effects of
an industrial disaster of unprecedented proportion—or something else entirely.
Id. at 572–73.
195. Matthew Mall, Derailing the Gravy Train: A Three-Pronged Approach to End Fraud in
Mass-Tort Medical Diagnosing, 48 WM. & MARY L. REV. 2043, 2049–50 (2007); see also Eleanor
Barrett, Maybe This Time, BEST’S REVIEW, Dec. 1, 2005, at 102, 104 (noting that mass screenings are responsible for the increase in nonmalignant, unimpaired claims). Unimpaired
claims are typically generated by for-profit screening companies “whose sole purpose is to
identify large numbers of people who have minimal x-ray changes that are ‘consistent with’
prior asbestos exposure, thus providing the pretext for a lawsuit.” Mark A. Behrens & Phil
Goldberg, Asbestos Litigation: Momentum Builds for State-Based Medical Criteria Solutions to Address Filings by the Non-Sick, 20 MEALEY’S LITIG. REP. 33, 34 (2005).
196. David Hechler, Silica Plaintiffs Suffer Setbacks: Broad Effects Seen in Fraud Allegations,
NAT’L L.J., Feb. 28, 2005, at 1, Col. 1; see also Thomas A. Donovan, Can the Courts Prevent
Being Used as an Instrument to Perpetuate Fraud?, FED. LAW., Nov./Dec. 2005, at 5 (“Comments made by plaintiffs’ trial counsel in attempting to justify the silicosis claims—together
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were using the same methodology to generate claims for asbestos litigation.197 Evidence seems to support the conclusion that numerous
asbestos claims in the tort system are also unfounded.198 Studies examining asbestos-related diagnoses in the tort system show that 66%
to 97% are unfounded claims.199 For example, after 439 claimants
filed suit after a mass screening in 1986, neutral professors and radiologists examined their x-rays and concluded that, at most, 2.5% had
conditions consistent with asbestos exposure.200 The claimants’ diagnosing doctors, however, had diagnosed all 439 with an asbestos-related disease, which indicates that their diagnoses were “mistakenly
high.”201 Similarly, when the Manville Trust ordered independent experts to audit claimants’ medical evidence, the auditors concluded
that over 40% of submitted claims were inaccurate.202
2. The Prevalence of Retreaded Asbestosis Claims in the Silica MDL
Indicates that Fraudulent Diagnoses Are Not Limited to
Silica Litigation
The prevalence of retreaded asbestosis claims in the Silica MDL
suggests that fraudulent diagnoses also exist in asbestos litigation because having both diseases is clinically rare, and even plaintiffs’ trial
counsel “call[ed] into question the validity of thousands of asbestosis
claims.”203 In fact, at least 60% of the Silica MDL plaintiffs were asbestos retreads, which occurs when a claimant has already received comwith the overall similarity in the medical screening procedures used in preparing silicosis
and asbestosis claims—call into question the validity of thousands of asbestosis claims as
well.”).
197. See Donovan, supra note 196, at 7 (noting that Judge Jack’s findings in the Silica
MDL raised doubts about many diagnoses in asbestos litigation because the same plaintiffs’
firms and diagnosing doctors were involved in both).
198. See, e.g., Abadie v. Metro. Life Ins. Co., 784 So. 2d 46, 97 (La. Ct. App. 2001)
(describing how an expert in internal and pulmonary medicine testified that “most asbestos-related disease claims are specious because they are manufactured for the purpose of
litigation”); Joseph N. Gitlin et al., Comparison of “B” Readers’ Interpretations of Chest Radiographs for Asbestos Related Changes, 11 ACAD. RADIOLOGY 843, 843 (2004) (explaining that
asbestos claims generated by mass screenings are unreliable based on a study by independent consultants in chest radiology).
199. Parloff, supra note 122, at 96; see also Commission on Asbestos Litigation: Report to the
House of Delegates, 2003 AM. BAR ASS’N 8 (stating that the rate of diagnoses generated by
mass screening companies is “startlingly high,” often exceeding 50% and sometimes reaching 90%); Pendell, supra note 52, at 5 (noting that several major audits of asbestos and
silicosis diagnoses indicate a high rate of false positives).
200. R.B. Reger et al., Cases of Alleged Asbestos-Related Disease: A Radiologic Re-Evaluation, 32
J. OCCUPATIONAL MED. 1088, 1088–89 (1990).
201. Id. at 1089–90.
202. Pendell, supra note 52, at 6–7.
203. Donovan, supra note 196, at 5, 7.
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pensation for an asbestos-related injury.204 In response to one
screening company’s asbestos retreads, Judge Jack observed that “a
golfer is more likely to hit a hole-in-one than an occupational
medicine specialist is to find a single case of both silicosis and asbestosis . . . [but this screening company] parked a van in some parking lots
and found over 4,000 such cases.”205 Because having both asbestosis
and silicosis is a clinical rarity,206 one could reasonably conclude that
either the silicosis or asbestosis diagnoses—if not both—are fraudulent. In fact, in response to Judge Jack’s troubling discovery, plaintiffs’ counsel admitted that the prior asbestosis diagnoses were
probably unfounded.207 Furthermore, when an independent, blind
panel of physicians reviewed 492 x-rays that had been generated by
physicians involved in both the Silica MDL and prior asbestos litigation, the experts found that only 4.5% of the x-rays showed signs of
asbestosis.208 Thus, due to evidence that fraudulent diagnoses were
used in asbestos litigation, using the tort system as a model to predict
future legitimate claims is unreliable.
3. Since Judge Jack Handed Down Her Opinion in the Silica MDL,
Others Have Revealed Additional Fraudulent Practices in
Asbestos Litigation
Since Judge Jack published her opinion in the Silica MDL, others
have exposed additional fraudulent occurrences in asbestos litigation.
In December 2005, in the Northern District of West Virginia, CSX
Transportation, Inc. (“CSX”) claimed that a law firm—in conjunction
with Dr. Ray Harron—filed fraudulent asbestosis claims against the
company.209 CSX proved that one plaintiff, who had tested negative
for asbestosis, had used a second claimant’s positive x-ray to settle his
fraudulent claim for $8000.210 Additionally, in January 2007, Judge
Harry Hanna of the Cuyahoga County Court of Common Pleas disqualified Brayton Purcell, a plaintiffs’ firm specializing in asbestos litigation, because the firm had filed claims against many different
204. Maron & Jones, supra note 120, at 259.
205. In re Silica Prods. Liab. Litig., 398 F. Supp. 2d 563, 603 (S.D. Tex. 2005).
206. Id. at 595.
207. Dunbar, Institutional Response, supra note 123, at 8.
208. Donovan, supra note 196, at 7.
209. CSX Transp., Inc. v. Gilkison, No. 5:05CV202, 2009 U.S. Dist. LEXIS 66995, at *3–4
(N.D. W. Va. July 30, 2009).
210. Linda Harris, Federal Jury Clears Man in CSX Asbestos Case, STATE J., Aug. 14, 2009,
http://statejournal.com/story.cfm?func=viewstory&storyid=64683&catid=166. CSX had
been unable to identify the “ghost claim” because it had been inundated by thousands of
asbestosis claims. Wylie et al., supra note 26, at 16.
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asbestos bankruptcy trusts “even though it could not have been possible for the underlying plaintiff to have suffered exposure from the
products of all of the defendants.”211 These incidents reveal that
fraudulent diagnoses are neither limited to silica cases nor to Judge
Jack’s courtroom.212
Unfortunately, misbehavior is not limited to plaintiffs’ firms,
screening companies, and their diagnosing doctors; it also occurs
within chambers. In 2003, Allegheny County Common Pleas Judge
Joseph Jaffe pled guilty to extortion.213 In charge of the 2200-case
asbestos docket in Pittsburgh, Judge Jaffe solicited bribes from plaintiffs’ counsel in exchange for influence in his courtroom.214 For these
reasons, relying on the tort system to predict the number of legitimate
claims that would be filed in the administrative system is improper.
Unless fraudulent asbestos claims in the tort system are taken into account, using the tort system would result in an overestimate of legitimate claims.
B. Judge Jack’s Scathing Opinion Suggests that Fewer Asbestos Claims
Will Be Filed in the Future
Judge Jack’s opinion in the Silica MDL, commended as a giant
stride toward reducing fraudulent and unethical conduct in mass
torts, will likely lead to a reduction in asbestos claims because the use
of mass screenings is no longer practicable and filing unimpaired
nonmalignant claims is no longer profitable for plaintiffs’ counsel.215
Judge Jack’s criticism of the mass screenings used in the Silica MDL
has echoed throughout the legal community.216 After conducting
court depositions, she suggested that “in every case involving a screen-

211. Mark D. Taylor, As the Wave of Asbestos Bankruptcies Recedes: What Have We Learned?, 6
MEALEY’S ASBESTOS BANKR. REP. 2 (2007).
212. Additionally, even before Judge Jack uncovered massive fraud in the Silica MDL,
United States District Court Judge Carl Rubin called into question the legitimacy of asbestos-related claims. See Lester Brickman, On the Theory Class’s Theories of Asbestos Litigation: The
Disconnect Between Scholarship and Reality, 31 PEPP. L. REV. 33, 104 (2003) [hereinafter Brickman, Theories] (noting that when Judge Rubin substituted impartial medical experts to
review the plaintiffs’ claims, those experts found that only 15% had asbestosis).
213. Wylie et al., supra note 26, at 16.
214. Id.
215. See infra Part V.B.1–2.
216. See Behrens & Goldberg, The Tide, supra note 102, at 493 (“Another event that
should accelerate the demise of mass screenings was a watershed ruling in June 2005 by the
manager of the federal silica multi-district litigation docket, U.S. District Judge Janis Graham Jack of the Southern District of Texas.”).

R

R

\\server05\productn\M\MLR\69-1\MLR112.txt

188

unknown

Seq: 27

MARYLAND LAW REVIEW

25-NOV-09

9:54

[VOL. 69:162

ing company, the diagnoses were essentially manufactured on an assembly line.”217
1. Using Mass Litigation Screenings to Recruit Claimants Is No
Longer Practicable Since Judge Jack Denounced the Practice
By exposing the abuses prevalent in mass screening practices,
Judge Jack’s scathing opinion has likely rendered the use of mass
screenings obsolete.218 Although the use of attorney-sponsored
screenings had already begun to decline before 2005, they are likely to
decline even more since Judge Jack published her opinion because
the practice is now associated with scandal.219 The decline of mass
litigation screenings is important because, as the RAND Institute of
Civil Justice has recognized, the exponential growth of asbestos litigation can be attributed to increased filings of nonmalignant claims,
which are generated by mass screenings.220 In fact, more than 90% of
the last 200,000 claims filed with the Manville Trust resulted from attorney-sponsored mass screenings, and more than 90% of all claims
alleged only nonmalignant asbestos disease.221 Thus, in order to use
the Manville Trust as a model to predict future legitimate filings in the
administrative system, claims generated from screenings should be
discounted. Furthermore, because the vast majority of nonmalignant
claims are filed by unimpaired plaintiffs,222 there will be fewer compensable claims in the administrative system because the unimpaired
are not substantially compensated under the FAIR Act.223 Thus, the
demise of mass screenings will significantly reduce the number of asbestos claims filed in both the tort system and bankruptcy trusts,
which should be taken into account before these systems are used as
models to predict future asbestos filings.
217. In re Silica Prods. Liab. Litig., 398 F. Supp. 2d 563, 633 (S.D. Tex. 2005) (emphasis
added).
218. See Patrick M. Hanlon & Elizabeth Runyan Geise, Asbestos Reform—Past and Future,
22 MEALEY’S LITIG. REP. 9 (2007) (discussing how the screenings have been abashed by the
opinion); see also Brickman, Applicability, supra note 104, at 314 (“The specter of facilitating
the emergence of another entrepreneurial claim generation process will undoubtedly affect many judges’ discretionary decisions that will determine the scope of mass tort
litigations.”).
219. Hanlon & Geise, supra note 218, at 9.
220. RAND 2005, supra note 22, at 73–74.
221. S. REP. NO. 108-118, at 84 (2003).
222. Id. at 68; see also In re Joint E. & S. Dist. Asbestos Litig., 237 F. Supp. 2d 297, 306
(E.D.N.Y. 2002) (explaining that the asbestos litigation crisis was caused by filings generated by claimants who were asymptomatic).
223. See Fairness in Asbestos Injury Resolution Act of 2006, S. 3274, 109th Cong.
§ 131(b)(5) (explaining that claimants with “asymptomatic exposure” are only eligible for
medical monitoring expenses).
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Current trends in asbestos litigation, which show dramatically reduced filings by unimpaired claimants, support the prediction that
the demise of mass screenings will result in fewer claims. Since 2001,
large defendant companies have reported an 80% reduction in asbestos filings and reported dismissal rates generally exceeding 75%.224 In
2003, the Manville Trust received approximately 90,000 claims, but
received less than 10,000 in 2006.225 Additionally, jurisdictions that
were previously overwhelmed by asbestos filings now report more
manageable numbers. For example, asbestos cases in Fulton County,
Georgia, have dropped from 1200 to about one dozen.226 Florida,
which used to get approximately 500 new asbestos cases per month,
now only receives forty to sixty new filings per month.227 Similarly,
Mississippi’s asbestos filings decreased from a few thousand to a few
hundred in 2005.228 Even insurance companies have reported a reduction in asbestos claims. In June 2006, during a Senate hearing on
the FAIR Act, an executive of Liberty Mutual Insurance testified that
claims have dramatically decreased, including a 90% and a 65% decrease in Mississippi and Texas, respectively.229
In addition to the reduction in unimpaired claimants, the demise
of mass screenings should also reduce the prevalence of impaired,
nonmalignant cases—and possibly asbestos-related cancers as well.230
Because plaintiffs’ firms generally found impaired claimants as a byproduct of mass screenings, eliminating screenings will also reduce
impaired claimants’ filings.231 Therefore, although asbestos-related
claims have already dropped dramatically, it is reasonable to expect
future reductions as well because “after Judge Jack’s groundbreaking
revelations of massive double-dipping . . . the tort bar has had to tread
more carefully.”232 The current sense of scandal arising from Judge
224. Robin Cantor & Mary Lyman, Asbestos and State Tort Reforms, 20 JOHN LINER REV. 39,
43 (2007).
225. Mass Torts Subcomm., Overview of Asbestos Claims Issues and Trends, 2007 AM. ACAD.
OF ACTUARIES 17. The Manville Trust functions as a “bellwether” for trends and patterns in
asbestos litigation; thus, data from the trust can be used to gauge claim filing activity within
the tort system. Cantor & Lyman, supra note 224, at 42.
226. Chris Schmitt & Jillian Aldebron, Asbestos Cases in the Court: No Logjam, 2006 PUB.
CITIZEN 15.
227. Id. at 16.
228. Id. at 16–17.
229. The Fairness in Asbestos Injury Resolution Act of 2006: Hearing on S. 3274 Before the S.
Comm. on the Judiciary, 109th Cong. 16–17 (2006) (statement of Edmund F. Kelly, Chairman, Liberty Mutual Life Insurance).
230. Hanlon & Geise, supra note 218, at 9.
231. Id.
232. Wylie et al., supra note 26, at 22; see also Cantor & Lyman, supra note 224, at 42–43
(explaining that recent tort reform, including Judge Jack’s influential opinion, has re-
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Jack’s excoriating opinion has quashed the use of mass screenings to
recruit litigants, and it is questionable whether these practices will
ever make a comeback.233
2. Filing Unimpaired Nonmalignant Asbestos Claims Is No Longer
Profitable Because Such Claims Are Scrutinized More Closely
Since Judge Jack’s Opinion
The demise of mass litigation screenings inhibits the asbestos
bar’s ability to recruit thousands of unimpaired, nonmalignant claimants, and therefore plaintiffs’ firms will most likely find that it is no
longer profitable to file such claims. Because of Judge Jack’s findings,
courts are willing to scrutinize unimpaired claimants more closely,234
resulting in more costs than benefits in bringing an unimpaired
nonmalignant claim.235 Additionally, evidence shows that defendants
have gained confidence from Judge Jack’s opinion and increasingly
contest plaintiffs’ claims by requesting a broader range of discovery in
the pretrial phase.236 Based on Judge Jack’s findings of fraud, defend-

sulted in a dramatic reduction of asbestos claims over the last few years); Hanlon, Wrestling,
supra note 160, at 1206–07 (“[A]s a result of . . . the increasing scandal that began to be
associated with asbestos litigation, filings plummeted.”); Hensler, supra note 166, at 279
(“In the past several years, the number of new cases filed annually has dropped dramatically . . . [and c]harges of fraudulent claims associated with mass screenings are said to
have disrupted those practices.”).
233. Hanlon & Geise, supra note 218, at 9.
234. See, e.g., Mass Torts Subcomm., Overview of Asbestos Claims Issues and Trends, 2007
AM. ACAD. OF ACTUARIES 6 (predicting that Judge Jack’s findings will lead to increased
medical evidentiary standards for both silica and asbestos claims); Mass Torts Subcomm.,
Current Issues in Asbestos Litigation, 2006 AM. ACAD. OF ACTUARIES 8 (asserting that Judge
Jack’s findings led to heightened scrutiny of silica and asbestos claims, which will probably
affect whether and how mass litigation screenings are performed in the future).
235. Dunbar, Institutional Response, supra note 123, at 20.
236. See, e.g., Mount McKinley Ins. Co. v. Pittsburgh Corning Corp., No. 06cv1085, 2006
WL 2850573, at *1 (W.D. Pa. Oct. 3, 2006) (relying on In re Silica, defendants requested
discovery to investigate possible medical fraud that had been found in nationwide asbestos
litigation); In re G-I Holdings, Nos. 01-30135(RG), 01-38790(RG), 2006 WL 2403531, at
*4–6 & n.11 (Bankr. D. N.J. Aug. 11, 2006) (believing claims against them to be illegitimate, defendant debtors sought increased pretrial discovery, especially where players denounced by Judge Jack were involved); Lopez v. City of Houston, No. H-03-2297, 2006 WL
1663374, at *7 (S.D. Tex. June 12, 2006) (relying on In re Silica, defendants challenged the
methodology of plaintiffs’ experts); In re Welding Fume Prods. Liab. Litig., No. 1:03 CV
17000, MDL NO. 1535, 2006 WL 1173960, at *7 (N.D. Ohio Apr. 5, 2006) (claiming that
plaintiffs’ medical screenings were similar to those condemned by Judge Jack); Ballard v.
Illinois Central R.R., 2006 U.S. Dist. LEXIS 51311, at *11–12 & n.2, 17 (N.D. Ala. Mar. 9,
2006) (granting defendants’ request to depose a diagnosing doctor denounced by Judge
Jack and allowing for discovery on diagnosing doctors).
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ants’ challenges to questionable diagnoses are more likely to be
deemed credible by judges.237
United States District Court Judge James Giles of the Eastern District of Pennsylvania exemplifies the use of stricter scrutiny in response to Judge Jack’s opinion. In charge of the asbestos multidistrict
litigation, Judge Giles had always been cautious about permitting discovery, stating, “I do not presume that there is fraud in mass tort
litigation.”238 More recently, however, Judge Giles recognized that
“[c]urrent litigation efforts in this court and in the silica litigation
have revealed that many mass screenings lack reliability and accountability and have been conducted in a manner which failed to adhere to
certain necessary medical standards and regulations.”239 With these
new findings in mind, Judge Giles agreed to conduct hearings on the
evidentiary sufficiency of nonmalignant diagnoses supported by mass
screenings.240
In addition to Judge Giles, others have changed their pretrial and
trial procedures in response to Judge Jack’s findings in the Silica
MDL. For example, in Broward County, Florida, a trial judge issued a
case management order in the wake of Judge Jack’s opinion, causing
dozens of plaintiffs to dismiss their cases.241 In Philadelphia County,
Pennsylvania, after the court allowed close scrutiny of the claimants’
diagnoses through a case management order, dozens of plaintiffs dismissed their cases, and the defendants found that approximately twothirds of the claimants were asbestos retreads.242 Similarly, in the
Court of Common Pleas in Cuyahoga County, Ohio, a judge dismissed
approximately 3755 asbestos cases after the claimants’ diagnosing doctors—many of whom were denounced in Judge Jack’s opinion—refused to testify as to their diagnosing practices.243 The court put
another 35,000 asbestos cases on hold until the claimants could get
positive diagnoses from doctors other than those criticized by Judge
Jack.244
237. Kara Sissell, Grace Settles Asbestos Claims; Advances Chapter 11 Exit, CHEMICAL WK.,
Apr. 2008, at 9 (claiming that Judge Jack’s opinion established judicial precedent that
makes it more likely for defendants to prevail when challenging questionable claims in
court).
238. Brickman, Disparities, supra note 52, at 522 n.27.
239. In re Asbestos Prods. Liab. Litig. (No. VI), No. MDL 875, 2007 WL 2372400, at *2
(E.D. Pa. May 31, 2007) (Admin. Order No. 12).
240. Id.
241. Carlyn Kolker, Lighter Caseloads for All: Judge Jack’s 2005 Ruling Continues to Snuff Out
Silica Cases Nationwide, AM. LAW., July 2006, at 17.
242. Id.
243. Behrens & Goldberg, The Tide, supra note 102, at 494.
244. Id. at 494–95.
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Judge Jack’s Denouncement of Nine Diagnosing Doctors Will
Dramatically Reduce Future Asbestos Claims

Judge Jack weakened numerous diagnosing doctors’ credentials,
which should reduce future asbestos-related filings because these individuals account for a significant portion of asbestos claims in the tort
and bankruptcy systems. After Judge Jack handed down her ruling in
2005, authorities launched grand jury investigations to consider bringing criminal charges arising out of the Silica MDL.245 As a result, the
Manville Trust, the Eagle-Picher Asbestos Settlement Trust, and the
Celotex Asbestos Settlement Trust announced that they would no
longer accept medical reports or diagnoses from doctors or screening
companies denounced by Judge Jack.246 As a result of this decision, a
major source of asbestos claims has been eliminated. For example,
Dr. Ray Harron, who diagnosed approximately 78% of the silicosis
claimants in the Silica MDL, is responsible for about 10% of the
claims filed with the Manville Trust.247 In fact, Dr. Ray Harron, Dr.
James Ballard, Dr. George Martindale, and Dr. W. Allen Oaks submitted at least 66,000 claims to the Manville Trust.248 Additionally, the
following five doctors denounced by Judge Jack are responsible for
approximately 80% of the claims submitted to Owens Corning before
it filed for bankruptcy: Dr. Ray Harron, Dr. Jay Segarra, Dr. Richard
Keubler, Dr. Philip Lucas, and Dr. James Ballard.249
VI.

CONCLUSION

Opponents of the FAIR Act feared that the projection of $140
billion was too low to compensate all deserving claimants.250 Their
fear was based on precedent trust funds—the Manville Trust, the
Black Lung Program, the Vaccine Injury Compensation Program, the
Energy Employees Occupational Illness Compensation Program, and
the Radiation Exposure Compensation Program—that all needed
Congress to bail out their “exploding costs with tax dollars.”251 For
245. Pendell, supra note 52, at 9.
246. Behrens & Goldberg, The Tide, supra note 102, at 494. These doctors include the
following: Dr. James Ballard, Dr. Kevin Cooper, Dr. Todd Coulter, Dr. Andrew Harron, Dr.
Ray Harron, Dr. Glynn Hilbun, Dr. Barry Levy, Dr. George Martindale, and Dr. W. Allen
Oaks. Letter from David Austern, President, Claims Resolution Management Corporation
(Sept. 12, 2005) (on file with author).
247. Parloff, supra note 122, at 96.
248. Id.
249. Brickman, Disparities, supra note 52, at 521 n.19.
250. See supra Part IV.
251. 152 CONG. REC. S1135, 1158 (daily ed. Feb. 14, 2006) (statement of Sen. Gregg); see
also Hanlon, Elegy, supra note 75, at 568 (“Beginning at least with the Black Lung program
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example, the Manville Trust predicted that it would receive approximately 200,000 claims, but it actually received about two million.252
While the fear of underestimating asbestos liability is understandable,
this time, Congress can be confident that the CBO’s estimate of $140
billion could cover future asbestos costs. In fact, the Silica MDL may
even indicate that this estimate is more than sufficient.
Although claims projections for previous asbestos trusts were too
low, the underestimation occurred because the trusts were unable to
predict that an extraordinary number of nonmalignant claims would
be filed.253 Predicting future cancer claims, however, has not been
problematic.254 Thus, because Judge Jack’s findings in the Silica MDL
have reduced and will continue to reduce these unimpaired,
nonmalignant claims,255 concern about underestimation should be diminished. Furthermore, in response to Judge Jack’s findings of fraud,
the FAIR Act incorporated provisions that would prevent illegitimate
claims from being compensated.256 Thus, the Fund would not be depleted by unfounded claims, which is important because “[t]he principal reason why all attempts to predict the total number of asbestos
claims have proven woefully inadequate is [because] claims are being
compensated for illnesses that . . . either are not caused by asbestos or
do not result in a significant impairment . . . .”257 Here, however,
Congress is better able to predict future asbestos filings because, since
Judge Jack’s ruling, claims based on unfounded medical evidence are
no longer acceptable. As such, previous trusts funds, including the
Manville Trust, are not accurate indicia of future compensable asbestos filings because the overwhelming majority of nonmalignant claims
paid by the Manville Trust went to unimpaired claimants.258 Under
the FAIR Act, unimpaired claimants do not receive compensation beyond medical monitoring costs, and this should be taken into
account.259
To estimate the number of future asbestos claims that would be
filed under the FAIR Act, the CBO assumed that the ratio of
nonmalignant to malignant claims “would be similar to the historical
there has been a history of underpredicting the number of claims that would have to be
paid under administrative schemes.”).
252. 152 CONG. REC. S1135, 1161 (daily ed. Feb. 14, 2006) (statement of Sen. Durbin).
253. Hanlon, Elegy, supra note 75, at 568–69.
254. Id.
255. See supra Part V.
256. See supra Part II.
257. Brickman, Theories, supra note 212, at 38 n.12.
258. 152 CONG. REC. S1135, 1148 (daily ed. Feb. 14, 2006) (statement of Sen. Leahy).
259. Id.
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ratio of claims compensated by existing bankruptcy trusts.”260 The
CBO’s assumption is improper, however, because it does not accord
enough importance to Judge Jack’s decision, which indicates that the
number of legitimate nonmalignant claims should substantially decrease.261 In fact, between 2003 and 2005, the ratio of nonmalignant
to malignant claims has fallen from 9:1 to 2.65:1.262 Additionally, the
Eagle-Picher Trust and Celotex Asbestos Settlement Trust have experienced a reduction in claims ranging between 25% to 35%.263
Although Senator Specter has attempted to revive the bill,264
Democrats’ current control of Congress, as well as the election of a
Democrat President, will most likely impede the enactment of an administrative solution in the near future.265 Despite the positive events
resulting from Judge Jack’s findings, it is possible that the creative asbestos bar will find new ways to profit, and in the meantime, the litigation may grow more intense.266 Unfortunately, it seems that any
chances that the FAIR Act will be revived are slim.267

260. 152 CONG. REC. S875, 891 (daily ed. Feb. 9, 2006) (statement of Sen. Specter).
261. See supra Part V.
262. Lester Brickman, An Analysis of the Financial Impact of S. 852: The Fairness in Asbestos
Injury Resolution Act of 2005, 27 CARDOZO L. REV. 991, 1012 n.93 (2005).
263. Id.
264. 3 DAVID L. FAIGMAN ET AL., MODERN SCIENTIFIC EVIDENCE § 26:1 n.33 (2005–2006
ed. & Supp. 2008).
265. See supra text accompanying notes 180–81.
266. Hanlon & Geise, supra note 218, at 12.
267. Cantor & Lyman, supra note 224, at 40.
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